Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies

Leukemia

Volumn 27, Issue 6, 2013, Pages 1301-1309

  Khan, S N ^a   Jankowska, A M ^a   Mahfouz, R ^a   Dunbar, A J ^a   Sugimoto, Y ^a   Hosono, N ^a   Hu, Z ^a   Cheriyath, V ^a   Vatolin, S ^a   Przychodzen, B ^a   Reu, F J ^a,b   Saunthararajah, Y ^a,b   O'Keefe, C ^a   Sekeres, M A ^b   List, A F ^c   Moliterno, A R ^d   McDevitt, M A ^d   Maciejewski, J P ^a,b   Makishima, H ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

mutations; myeloid malignancies; polycomb repressive complex 2; spliceosome

Indexed keywords

HISTONE H3; HISTONE H3 LYSINE 27; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR HOXA9; UNCLASSIFIED DRUG;

ARTICLE; CANCER PROGNOSIS; CELL RENEWAL; CHROMATIN; CHROMOSOME 7; CONTROLLED STUDY; DIPLOIDY; DOWNSTREAM PROCESSING; EPIGENETICS; GENE DELETION; GENE LOCUS; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC REGULATION; GENETIC TRANSCRIPTION; HOMOZYGOTE; HOX GENE; HUMAN; MISSENSE MUTATION; MUTANT; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLICEOSOME; STEM CELL;

BLOTTING, WESTERN; CHROMOSOMES, HUMAN, PAIR 7; EPIGENESIS, GENETIC; HEMATOLOGIC NEOPLASMS; HISTONES; HUMANS; MUTATION; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84878921669     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.80     Document Type: Article

References (45)

1. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088. (Pubitemid 27132124)
2. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083.
3. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
4. Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychodzen B et al. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood 2012; 119: 6109-6117.
5. Klampfl T, Harutyunyan A, Berg T, Gisslinger B, Schalling M, Bagienski K et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 2011; 118: 167-176.
6. Dohner K, Brown J, Hehmann U, Hetzel C, Stewart J, Lowther G et al. Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders. Blood 1998; 92: 4031-4035. (Pubitemid 28544315)
7. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722-726.
8. Makishima H, Jankowska AM, Tiu RV, Szpurka H, Sugimoto Y, Hu Z et al. Novel homo-and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 2010; 24: 1799-1804.
9. Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tonnissen ER et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010; 42: 665-667.
10. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181-185.
11. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-629.
12. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003; 100: 11606-11611. (Pubitemid 37205983)
13. Wagener N, Holland D, Bulkescher J, Crnkovic-Mertens I, Hoppe-Seyler K, Zentgraf H et al. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Int J Cancer 2008; 123: 1545-1550.
14. Bodor C, O'Riain C, Wrench D, Matthews J, Iyengar S, Tayyib H et al. EZH2 Y641 mutations in follicular lymphoma. Leukemia 2011; 25: 726-729.
15. Velichutina I, Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 2010; 116: 5247-5255.
16. O'Carroll D, Erhardt S, Pagani M, Barton SC, Surani MA, Jenuwein T. The polycombgroup gene Ezh2 is required for early mouse development. Mol Cell Biol 2001; 21: 4330-4336. (Pubitemid 32565314)
17. Score J, Hidalgo-Curtis C, Jones AV, Winkelmann N, Skinner A, Ward D et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood 2012; 119: 1208-1213.
18. Beekman R, Valkhof MG, Sanders MA, van Strien PM, Haanstra JR, Broeders L et al. Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. Blood 2012; 119: 5071-5077.
19. Makishima H, Rataul M, Gondek LP, Huh J, Cook JR, Theil KS et al. FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q). Leuk Res 2010; 34: 447-453.
20. Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/ myeloproliferative neoplasms. Blood 2009; 113: 6403-6410.
21. Vatolin S, Khan SN, Reu FJ. Direct chromatin PCR (DC-PCR): hypotonic conditions allow differentiation of chromatin states during thermal cycling. PLoS One 2012; 7: e44690.
22. Kotake Y, Cao R, Viatour P, Sage J, Zhang Y, Xiong Y. pRB family proteins are required for H3K27 trimethylation and polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. Genes Dev 2007; 21: 49-54. (Pubitemid 46089706)
23. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 2006; 20: 1123-1136.
24. Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu Kar S, Jerez A et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012; 119: 3203-3210.
25. Thol F, Kade S, Schlarmann C, Loffeld P, Morgan M, Krauter J et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012; 119: 3578-3584.
26. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496-2506.
27. Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011; 118: 5227-5234.
28. Grossmann V, Kohlmann A, Eder C, Haferlach C, Kern W, Cross NC et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in480% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia 2011; 25: 877-879.
29. Tiu RV, Visconte V, Traina F, Schwandt A, Maciejewski JP. Updates in cytogenetics and molecular markers in MDS. Curr Hematol Malig Rep 2011; 6: 126-135.
30. Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011; 118: 3932-3941.
31. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011; 29: 573-582.
32. Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011; 25: 1200-1202.
33. Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 2011; 29: 2499-2506.
34. Gelsi-Boyer V, Trouplin V, Roquain J, Adelaide J, Carbuccia N, Esterni B et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 2010; 151: 365-375.
35. Chen H, Rossier C, Antonarakis SE. Cloning of a human homolog of the Drosophila enhancer of zeste gene (EZH2) that maps to chromosome 21q22.2. Genomics 1996; 38: 30-37. (Pubitemid 26423910)
36. Laible G, Wolf A, Dorn R, Reuter G, Nislow C, Lebersorger A et al. Mammalian homologues of the polycomb-group gene enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres. EMBO J 1997; 16: 3219-3232. (Pubitemid 27234960)
37. Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell 2004; 15: 57-67. (Pubitemid 38850219)
38. Cha TL, Zhou BP, Xia W, Wu Y, Yang CC, Chen CT et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 2005; 310: 306-310. (Pubitemid 41457195)
39. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64-69.
40. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365: 1384-1395.
41. Konuma T, Oguro H, Iwama A. Role of the polycomb group proteins in hematopoietic stem cells. Dev Growth Differ 2010; 52: 505-516.
42. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010; 7: 299-313.
43. Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol 2001; 21: 224-234.
44. Calvo KR, Sykes DB, Pasillas M, Kamps MP. HOXA9 immortalizes a granulocytemacrophage colony-stimulating factor-dependent promyelocyte capable of biphenotypic differentiation to neutrophils or macrophages, independent of enforced MEIS expression. Mol Cell Biol 2000; 20: 3274-3285. (Pubitemid 30215039)
45. Kruidenier LA, Chung CW, Cheng Z, Liddle J, Che K, Joberty G et al. Selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 2012; 488: 404-408.